Acumen Pharmaceuticals Inc (ABOS) - Total Assets
Based on the latest financial reports, Acumen Pharmaceuticals Inc (ABOS) holds total assets worth $133.63 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Acumen Pharmaceuticals Inc balance sheet quality to measure how much of total assets are equity-financed.
Acumen Pharmaceuticals Inc - Total Assets Trend (2019–2025)
This chart illustrates how Acumen Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Explore ABOS long-term investment intensity to see how much of total assets are deployed in long-term investments.
Acumen Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Acumen Pharmaceuticals Inc's total assets of $133.63 Million consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 44.0% |
| Accounts Receivable | $625.00K | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $29.00K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Acumen Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Acumen Pharmaceuticals Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Acumen Pharmaceuticals Inc's current assets represent 99.5% of total assets in 2025, an increase from 98.0% in 2019.
- Cash Position: Cash and equivalents constituted 44.0% of total assets in 2025, down from 89.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Acumen Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Acumen Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €8.68 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Tourmaline Bio Inc.
NASDAQ:TRML
|
USA | $269.30 Million |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
|
China | CN¥1.32 Billion |
Acumen Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.55 | 8.02 | 15.62 |
| Quick Ratio | 4.55 | 8.02 | 15.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $103.86 Million | $135.63 Million | $66.05 Million |
Acumen Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Acumen Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.89 |
| Latest Market Cap to Assets Ratio | 1.26 |
| Asset Growth Rate (YoY) | -48.6% |
| Total Assets | $122.83 Million |
| Market Capitalization | $155.29 Million USD |
Valuation Analysis
Above Book Valuation: The market values Acumen Pharmaceuticals Inc's assets above their book value (1.26x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Acumen Pharmaceuticals Inc's assets decreased by 48.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Acumen Pharmaceuticals Inc (2019–2025)
The table below shows the annual total assets of Acumen Pharmaceuticals Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $122.83 Million | -48.60% |
| 2024-12-31 | $238.99 Million | -22.94% |
| 2023-12-31 | $310.12 Million | +57.75% |
| 2022-12-31 | $196.59 Million | -14.65% |
| 2021-12-31 | $230.33 Million | +418.42% |
| 2020-12-31 | $44.43 Million | +506.79% |
| 2019-12-31 | $7.32 Million | -- |
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement… Read more